Bli medlem
Bli medlem

Du är här


Redeye: Xbrane Biopharma - Still A Hidden Gem

Redeye remains positive on the investment case in Xbrane Biopharma following its Q3 2022 report. Only a few weeks remain until the anticipated approval of Ximluci by the European Commission, bringing the Q1 2023 launch in Europe closer. 2023 will be a pivotal year for Xbrane, and the share price is likely to follow, we judge.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.


Xbrane Biopharma - Still A Hidden Gem

Författare MFN